title: Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study.
abstract: OBJECTIVE
  To report on visual outcome of patients receiving an intravitreal injection of triamcinolone acetonide for treatment of diffuse diabetic macular oedema.
  
  
  METHODS
  Prospective, comparative, non-randomised clinical interventional study included 136 patients with diffuse diabetic macular oedema. Patients of the study group (97 eyes) received an intravitreal injection of 20-25 mg of triamcinolone acetonide and no other retinal treatment. Patients of the control group (69 eyes) received focal or panretinal laser treatment if indicated. Mean (standard deviation) follow up was 8.4 (SD 6.0) months (range 1.03-25.2 months).
  
  
  RESULTS
  Visual acuity (VA) increased significantly (p<0.001) in the study group with 66 (68%) eyes gaining in VA by at least two Snellen lines. In the control group, VA did not change significantly during the first 4 months of follow up, and decreased significantly (p<0.001) towards the end of the follow up. Difference in change of best VA was significant (p<0.001) between both groups. Correspondingly, the number of patients with VA improvement of two or more Snellen lines and visual loss of two or more Snellen lines, respectively, was significantly (p<0.001) higher and lower, respectively, in the study group.
  
  
  CONCLUSIONS
  Intravitreal triamcinolone acetonide can temporarily increase VA in some patients with diffuse diabetic macular oedema.
authors.affiliation: Department of Ophthalmology, Faculty of Clinical Medicine Mannheim of the University of Heidelberg, Heidelberg, Germany. Jost.Jonas@ma.augen.uni-heidelberg.de
authors.forename: J B
authors.initials: JB
authors.lastname: Jonas
authors.forename: I
authors.initials: I
authors.lastname: Akkoyun
authors.forename: I
authors.initials: I
authors.lastname: Kreissig
authors.forename: R F
authors.initials: RF
authors.lastname: Degenring
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D016009:Chi-Square Distribution; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D053685:Laser Therapy; D008268:Macular Degeneration / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018709:Statistics, Nonparametric; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000627:therapeutic use; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D000893:Anti-Inflammatory Agents; D014222:Triamcinolone Acetonide
references.citation: Ophthalmology. 1991 May;98(5 Suppl):807-22
references.pmid: 2062514
references.citation: Eur J Ophthalmol. 2003 Jul;13(6):575-6
references.pmid: 12948317
references.citation: Am J Ophthalmol. 2003 Feb;135(2):246-9
references.pmid: 12566041
references.citation: J Glaucoma. 2001 Aug;10(4):284-7
references.pmid: 11558812
references.citation: Am J Ophthalmol. 2001 Sep;132(3):425-7
references.pmid: 11530068
references.citation: J Cataract Refract Surg. 2002 Nov;28(11):2040-1
references.pmid: 12457682
references.citation: Arch Ophthalmol. 2001 Sep;119(9):1380-3
references.pmid: 11545651
references.citation: Br J Ophthalmol. 2003 Apr;87(4):462-8
references.pmid: 12642311
references.citation: Eur J Ophthalmol. 2003 Jun;13(5):468-73
references.pmid: 12841570
references.citation: Ophthalmology. 1992 May;99(5):753-9
references.pmid: 1594222
references.citation: Retina. 2000;20(5):554-5
references.pmid: 11039438
references.citation: Arch Ophthalmol. 2003 May;121(5):729-30
references.pmid: 12742856
references.citation: Retina. 2003 Feb;23(1):113-6
references.pmid: 12652245
references.citation: Br J Ophthalmol. 2003 Mar;87(3):361
references.pmid: 12598455
references.citation: Br J Ophthalmol. 2003 Jan;87(1):24-7
references.pmid: 12488256
references.citation: Am J Ophthalmol. 2004 Feb;137(2):367-8
references.pmid: 14962439
references.citation: Arch Ophthalmol. 2004 Feb;122(2):218-22
references.pmid: 14769599
references.citation: Br J Ophthalmol. 2002 Feb;86(2):247-8
references.pmid: 11815359
references.citation: Graefes Arch Clin Exp Ophthalmol. 2002 Oct;240(10):873-4
references.pmid: 12530461
references.citation: Ophthalmology. 2002 May;109(5):920-7
references.pmid: 11986098
references.citation: Am J Ophthalmol. 2003 Aug;136(2):384-6
references.pmid: 12888077
references.citation: Aust N Z J Ophthalmol. 1999 Dec;27(6):431-2
references.pmid: 10641903
references.citation: Retina. 2000;20(3):244-50
references.pmid: 10872928
references.citation: J Cataract Refract Surg. 2003 Jan;29(1):27-33
references.pmid: 12551663
references.citation: Arch Ophthalmol. 2003 Jan;121(1):57-61
references.pmid: 12523885
references.citation: Ophthalmology. 2001 Apr;108(4):765-72
references.pmid: 11297495
references.citation: Aust N Z J Ophthalmol. 1995 Nov;23(4):293-8
references.pmid: 11980075
references.citation: Ophthalmology. 2000 Nov;107(11):2024-33
references.pmid: 11054326
references.citation: Ophthalmology. 1991 May;98(5 Suppl):741-56
references.pmid: 2062510
references.citation: Graefes Arch Clin Exp Ophthalmol. 2002 Sep;240(9):782-3
references.pmid: 12271378
references.citation: Am J Ophthalmol. 2001 Apr;131(4):468-71
references.pmid: 11292410
references.citation: Br J Ophthalmol. 2002 May;86(5):527-9
references.pmid: 11973247
references.citation: Arch Ophthalmol. 2003 May;121(5):667-73
references.pmid: 12742844
references.citation: Graefes Arch Clin Exp Ophthalmol. 2001 Jul;239(6):464-5
references.pmid: 11561798
references.citation: Br J Ophthalmol. 2005 Jan;89(1):122
references.pmid: 15615762
references.citation: Ophthalmology. 2004 Feb;111(2):218-24; discussion 224-5
references.pmid: 15019365
references.citation: Clin Exp Ophthalmol. 2001 Feb;29(1):2-6
references.pmid: 11272779